Thanks for sharing. That article is a little better than the Emerald focused pieces we've read so far. Again, I hope elaboration on these "benefits" for Abattis is provided in time, but here are bullet points so far.. This is what we've received for 53% of Northern Vine.
* $2.5 million
* Emerald Health’s wealth of scientific knowledge, pharmaceutical connections, and access to capital
* Access to cannabis active ingredient based products, such as edibles, for testing and refining
That said, I just want to turn to this statement..
The company has always desired a strategic partner for its laboratory and has now partnered with one of the most experienced LPs in Canada.
Is Emerald truly one of the most experienced? Are there any well informed Emerald investors here that can verify that statement with facts, comparisons, figures, etc.. and, if possible, provide additional insight on where Emerald could take Northern Vine?